Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 55 Endometrial Neoplasms 7 Ovarian Neoplasms 5 Neoplasm Metastasis 5 Polycystic Ovary Syndrome 4 Neoplasms 4 Advanced Breast Cancer 4 Triple Negative Breast Neoplasms 3 Prostatic Neoplasms 3 Carcinoma, Intraductal, Noninfiltrating 3 Recurrence 2 Neoplasms by Site 2 Infertility 2 HR+/HER2- Breast Cancer 2 Estrogen Receptor-positive Breast Cancer 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms, Male 2 Breast Diseases 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sexual Dysfunctions, Psychological 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Low-Grade Serous Ovarian Cancer 1 Low Grade Serous Ovarian Carcinoma 1 Low Grade Serous Ovarian Cancer 1 Locoregional Recurrence 1 Leiomyoma 1

Interventions

ribociclib 1 Letrozole 1 Goserelin 1 Chemotherapy, Adjuvant 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HER2 Negative Breast Cancer × Letrozole × 90 days × Clear all

NCT06953882 2026-05-26

SELECT

Yale University

Phase 2 Recruiting

HER2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡